<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; sharpening</title>
	<atom:link href="http://www.tapanray.in/tag/sharpening/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Biosimilars –Indian Pharmaceutical Companies are sharpening their focus on fast growing Oncology segment</title>
		<link>http://www.tapanray.in/biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment</link>
		<comments>http://www.tapanray.in/biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment/#comments</comments>
		<pubDate>Mon, 13 Jul 2009 01:30:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[fast]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[sharpening]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[their]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=836</guid>
		<description><![CDATA[The global market for Bio-pharmaceuticals is estimated to be around US$ 50 billion by the next year. Currently about 25% of New Molecular Entities (NMEs) under development are of biotech origin. Indian pharmaceutical majors like Dr. Reddy’s Laboratories (DRL), Reliance &#8230; <a href="http://www.tapanray.in/biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
